Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

October 20, 2022

New York Stock Exchange US Consumer Staples Tobacco earnings 67 min

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, everyone, and thanks for being here. We put out a press release earlier today with all the specifics about how we performed in the third quarter of 2022. That release is available at pmi.com. If you need a glossary of terms — this covers what we mean by reduced-risk products, or RRPs, plus adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures, along with extra smoke-free volume and net revenue data — you'll find it at the back of the webcast slides for today, which are up on our site. Except where we say otherwise, whenever we mention IQOS, we're talking about our IQOS heat-not-burn products, and whenever we mention smoke-free products, we mean our RRPs. The growth rates we show on an organic basis are currency neutral adjusted results, leaving out acquisitions and disposals. Any figures and comparisons given on a pro forma basis completely leave out PMI's operations in Russia and Ukraine. As we noted before, beginning in the second quarter of 2022, and on a comparative basis, PMI leaves amortization and impairment of acquired intangibles out of its adjusted results. Remarks today include forward-looking statements and projections of future results. Please take a look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. With me today are Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial Officer. Jacek will be with us for the question and answer session. Emmanuel, over to you.

Emmanuel Babeau

executive
#2

Thanks, James, and hello everybody. With the certainty that we'll have complete control of IQOS — the top smoke-free product worldwide — in the United States, the biggest smoke-free market globally, starting April 30, 2024, today is a landmark moment in our path toward a smoke-free future. Yes, our agreement with Altria, announced today, eliminated the chance of a drawn-out legal battle to recover the U.S. rights to IQOS, which Altria had held before, tied to a performance milestone running through 2029. Our ambitions for a full-scale launch and swift expansion of IQOS across the U.S. market are substantial. Once we assume control, we'll make efficient use of the transition period to establish our commercial model along with the related organization and infrastructure, drawing on the deep experience we've gained in international markets; we view IQOS as the main vehicle for securing a leadership position in the U.S. smoke-free sector, and other items from our smoke-free portfolio will follow it; in that connection, Swedish Match provides an instant foothold in the oral category and win-win synergy at the sales force level. If, however, the offer doesn't succeed, we can definitely assemble a strong sales force within our commercial deployment engine throughout the transition period. Either way, we anticipate a quicker route to profitability with an appealing payback period on what we invest in IQOS, thanks to superior U.S. unit economics and the lack of a legacy cigarette business. I'll go into greater depth on that later; regarding Swedish Match, this morning we announced an update to our offer, with our best and final price set at SEK 116. Our revised offer kept a 90% acceptance condition, which matters greatly so we can capture the combination's full potential. Since we're nearing the close of the offer period, the higher offer is mainly meant to fairly mirror the greater net value to us of the share of Swedish Match cash flow denominated in U.S. dollars, reflecting currency shifts since we announced our initial offer in May. Equity markets, the global economy, and interest rates have likewise shifted unfavorably since that time. Because of this, we think the updated price — carrying a premium of 52.5% over the undisturbed share price before the initial offer — makes the proposition even more appealing for Swedish Match shareholders, while still delivering strong value creation for PMI shareholders. This is our best and final price, and we aim to close the deal next month to reach full ownership. Now to our Q3 earnings. We turned in another very strong quarter, with HTU volumes beating our forecast and solid gains in total volumes, market share, and combustible net revenues. With adjusted operating income margin matching expectations, that produced total Q3 adjusted diluted EPS of $1.53. That's near our record quarterly high, even with significant currency headwinds, and reflects a 0.6% improvement. IQOS kept up its outstanding results, with pro forma HTU shipment volume up 22% — clear evidence that our heat-not-burn lineup keeps getting stronger, with growth spread widely across major regions. In the markets where it has launched, IQOS ILUMA kept fueling expansion. On the combustibles side, we posted a solid showing: Q3 organic pro forma net revenue climbed past 4%, helped by pricing that accelerated to nearly 5%. Cigarette shipment volumes came in basically flat, and our category share rose, backed by Marlboro — proof the brand holds up even under today's economic circumstances. Now for the headline figures. On a pro forma basis, our Q3 volumes rose 2.3%, and 4.6% altogether once Russia and Ukraine are counted. Pro forma net revenues increased 6.9% organically, and 6.7% for PMI as a whole. Our total organic net revenue per unit was up 4.5% pro forma and 6.1% in total, even with device revenues lower. That shows how much heavier IQOS now weighs in our sales mix, plus a step up in combustible pricing. Organically, our Q3 adjusted operating income margin fell 100 basis points pro forma and 90 basis points in total, which is in line with what we expected. As we said before, this stems from device volume recovering, the investment behind the ILUMA launch — including higher unit costs at the start — supply chain disruption, particularly from the war in Ukraine, and rising inflationary pressure worldwide. Even with those headwinds, our strong top-line growth and continuing cost efficiency let us beat the currency neutral guidance we had given, posting adjusted diluted pro forma EPS of $1.33, which includes $0.23 of unfavorable currency, equal to 8.3% currency neutral growth. Counting Russia and Ukraine, adjusted diluted EPS comes to $1.53. A strong third quarter plus a robust H1 underpinned excellent delivery for the year to date. I'd point to pro forma volume growth of 3.4% and organic net revenue growth of 7.7%. Once again, that mirrors sustained strong IQOS performance, pricing, and combustible business recovery across many markets against a pandemic-affected comparison. Smoke-free net revenue accounted for roughly 30% of our year-to-date pro forma total, keeping us on track for our ambition of over 50% by 2025. On a pro forma basis, our year-to-date operating income margin contracted organically by 110 basis points, because of the factors I mentioned earlier. We're still on course to deliver $2 billion in cost savings across 2021 to 2023. Gross savings of $1.5 billion are already in hand, among them over $200 million in Q3. That lets us invest in the business while softening rising inflationary pressures. Year to date, currency neutral adjusted diluted EPS rose 9.7% to $4.11 pro forma, and 8.8% in total to $4.59 — an excellent performance. Now let's move to the pro forma full year outlook. With IQOS still expanding and combustibles showing solid momentum, we're lifting our top-line projection to shipment volume growth of +2% to +3% overall and organic net revenue growth of +6.5% to +8%. Though that top-line picture stays quite robust, we—much like numerous other multinationals—are confronting considerable inflationary pressure across the global economy, and our revised adjusted OI margin guidance captures that. During the third quarter, inflation within our cost of goods held in the mid-single-digit territory. Even so, cost pressures are mounting as we renegotiate pricing terms, particularly involving select direct materials, wages, energy, and transportation. On top of that, ILUMA's exceptionally rapid expansion in Japan and other launch markets drags margins down initially, since consumables carry more weight and both the device and the consumable cost more during the first 12 to 18 months of activation. As noted before, surging demand, worldwide supply chain upheaval, and halting induction HTU output in Russia together leave our supply chain short of full optimization. The upshot has been lower productivity plus various extra expenses, among them roughly $300 million tied to a substantial rise in air freight usage. This amounts to a 0.6% effect.

Emmanuel Babeau

executive
#3

We continue to anticipate that adjusted OI margin will recover in Q4, in part since commercial spend ran higher during that same stretch a year ago. All the same, the improvement we now project is smaller than what we had assumed earlier, meaning the pro forma adjusted organic operating income margin across the whole year comes out between flat and slightly negative. Even with that reduced margin outlook, top-line momentum remains powerful, and our 2022 guidance for pro forma adjusted diluted EPS growth is unchanged at +10% to +12%. Expressed in dollars, that translates into a pro forma adjusted diluted EPS estimate of $5.22-$5.33. That number incorporates an expected currency drag of $0.87 at prevailing exchange rates, largely driven by the euro and Japanese yen. Additional detail on how we calculate the FX effects appears on one of the appendix slides. Turning to total PMI, assuming Russia and Ukraine are included for the full year, we project adjusted diluted EPS of around $6, and that number reflects an anticipated currency headwind of roughly $0.80. Finally, because ILUMA continues to perform so well, together with the TEREA manufacturing in Russia I just mentioned, we are pushing to speed up induction consumable output even more. Moving and converting capacity from blade to induction brings particular inefficiencies and also caps ILUMA HTU availability; we are right-sizing inventory wherever possible so that consumer availability takes as little of a hit as we can manage. Even so, shipments remain limited by these problems, so our full-year HTU shipment outlook is being cut to a range of 89 to 91 billion units. Let me stress that this supply constraint is only temporary. Combustibles and tech trends are still firm, and HTU in-market sales volume should rise further still, exceeding +25% growth in Q4, while also growing sequentially versus Q3. Our company's capacity to generate cash remains outstanding, as the difficulties of recent years have demonstrated. The balance sheet and cash flow are still strong; year to date, we produced $7.7 billion of operating cash flow, which represents +6.5% growth on a currency-neutral basis. We are maintaining our forecast of approximately $10.5 billion in operating cash flow for the full year, despite an expected currency headwind of about $1.3 billion. Thus, for 2021 and 2022 taken together, we see a solid $22.5 billion. Certain factors made 2021's cash flow appear stronger than it truly was: $0.5 billion stemmed from one-time items, along with timing linked to certain cash flows that benefited 2021 while weighing on 2022, and a further $0.5 billion arose from working capital improvements. Yet measured against that unusually strong year, our 2022 forecast still demonstrates genuine underlying growth. One additional point I want to highlight: U.S. Because the bulk of our borrowing—more than 60%, including derivative overlays—is denominated in euro, a stronger dollar in fact benefits our net debt position. That advantage offsets the impact on earnings, and combined with strong cash flow, it produced a $1.5 billion reduction in net debt between December 2021 and the present, putting us below 1.6 times adjusted EBITDA on a rolling 12-month basis. This quarter demonstrates that we can keep our balance sheet healthy, reduce obligations, and continue putting money into business growth. We have also just raised our dividend on an annualized basis for a 15th year in a row, fulfilling our long-held promise of returning cash to shareholders. Back to the numbers: on a pro forma basis, shipment volume was up +2.3% in Q3 and +3.4% for the year to date, positioning us well to achieve volume growth for a second straight year on both a pro forma and total PMI basis. On HTUs, pro forma shipment volumes rose +21.9% in the third quarter and +15.8% year to date. Shipments have been choppier this year because of current supply chain conditions, but HTU IMS growth has stayed reliably strong, at +18.2% in Q3 and +19.2% year to date, with solid results across the EU region, Japan, and low and middle income markets. As I said earlier, we anticipate IMS growth will pick up further in the fourth quarter. Moving to combustibles now. During Q3, our portfolio posted solid pro forma organic net revenue growth of +4.1%, while pro forma shipment volume was essentially flat. Pro forma pricing increased to +4.9% in Q3 as we methodically respond to inflation. Australia, Germany, and the Philippines were meaningful contributors, and Indonesia recorded a positive quarterly variance for the first time since Q4 2019. For the entire year, we now anticipate pricing of roughly 4%. Thus far this year, our pro forma portion of the cigarette category has risen by 0.2 points. Marlboro drove that, with its volumes up almost 4% across total PMI. For the world's top cigarette brand, holding a premium position while consumers confront a challenging environment is a strong result. Because we lead in combustibles, we are better placed to steer as much switching as possible toward smoke-free products, and our continuing goal is a stable category share over the long term, even as IQOS cannibalization keeps weighing on it. By combining a steady combustible share with IQOS's ongoing growth, we are set to achieve total market share growth over time. We gained +0.5 points of pro forma share in Q3 and +0.6 points year to date, with major contributions from Italy, Indonesia, Japan, and Poland. Even as competition intensifies across many markets, our leading share of the growing heat-not-burn category has remained stable since the start of the year at approximately 75% and increased sequentially in the third quarter. This exceptional result stems from broader rollout of a two-tier HT portfolio, giving adult smokers an expanding range of innovative, high-quality cigarette alternatives. Wherever IQOS is available for purchase, PMI's heated tobacco units have once more locked in the number two spot among nicotine brands. On a sequential basis, share gained 0.2 points during Q3, reaching an all-time high of 7.7% once Russia and Ukraine are stripped out. Now for IQOS's performance: as of September 30, our count of IQOS users sits at roughly 19.5 million, again excluding Russia and Ukraine. That translates into around 0.5 million users gained during Q3, plus 2.7 million additional users for the year to date. If you look at the right-hand portion of the slide, you'll see that pro forma user growth generally decelerates in the third quarter each year, which is a reflection of seasonal patterns. As for that +0.5 million quarterly figure, it stands out as quite strong relative to history — although we should keep in mind that the impressive growth in Q3 2020 was aided by a catch-up effect after COVID-related restrictions on retail outlets and mobility were relaxed. One point we'd like to flag: we anticipate a meaningful pickup in user growth as we enter the fourth quarter of 2022. Over in the EU region, smoke-free net revenue accounted for nearly 40% of regional net revenue during the year so far, and across a number of markets that share sat comfortably above 50%. That result makes the direction we're headed unmistakable — our ambition of becoming predominantly smoke-free by 2025. In the EU, our third quarter HTU share rose +2 points versus the same period one year earlier, arriving at 7.3% of total cigarette and HTU industry volume. I'd also point out that sequential gain of 0.2 points, which stands out as a strong result given the usual seasonal pattern in the combustible category. What's even more notable: our adjusted IMS volume kept expanding quarter over quarter, hitting an all-time high of 8.7 billion units on a fourth quarter moving average basis, within a range of 89 billion to 91 billion units.

Emmanuel Babeau

executive
#4

We anticipate that IMS volume will keep rising in Q4, along with a matching gain in market share. Additional key cities and market share data can be found in the appendix. Turning to EU regulation, we take encouragement from the growing count of nations embracing multi-year fiscal frameworks that clearly distinguish smoke-free products, as seen in Romania's recent legislation. We look for the proposal on the EU Tobacco Excise Directive to come out by year-end and are hopeful for a comparable approach. Keep in mind that approval of the Tobacco Excise Directive demands unanimous backing from all 27 EU member states. Let's now turn to how Iluma has performed in the EU region. Iluma kept fueling user acquisition, the switching of existing users, and faster category growth in Spain as well as Switzerland. During Q3, both markets saw yet another quarter of robust sequential IMS volume growth, with TEREA offtake exit volume now representing the clear majority of HTU sales in each market. We also brought IQOS ILUMA to Greece at the close of June, with encouraging early results, and rolled the product out in Portugal earlier this month. In Japan, the adjusted total tobacco share for our HTU brand climbed by +2.8 points compared with the prior year quarter, reaching 23.6%. Just as in the EU, Q3 of last year brought an actual sequential share decline because of combustible seasonality, which makes the +0.7-point sequential gain this quarter a noteworthy accomplishment. IMS once more rose sequentially, hitting a record high of 8.3 billion units on the fourth quarter moving average. This stemmed from the impressive showing of IQOS ILUMA and ongoing growth in key cities like Tokyo. Heat-not-burn now accounts for more than one third of total tobacco in Japan, with IQOS increasingly fueling the unit growth. IQOS ILUMA marked its first anniversary of the Japan national launch in September and keeps displaying strong growth thanks to excellent conversion, consumer satisfaction, and retention rates. Our premium price series HTUs kept growing strongly in Q3 and reinforced their standing as both the second-largest nicotine brand and largest RRP brand in Japan, hitting an exit HTU share of 14.9%. Encouragingly, SENTIA HTUs have also expanded rapidly since the initial launch in April and national expansion in mid-July, fueling consumer acquisition in the mainstream price segment. We've exited Q3 with over 25% HTU offtake share, a record high, and continue to see a long runway of growth in Japan over the coming quarters. Beyond strong IQOS gains in developed countries, we keep seeing very promising growth in low and middle-income markets, which drove around 30% of the company's pro forma HTU growth in Q3. Given the large size of this market, the premium positioning of the existing IQOS portfolio and the relatively early stage of commercialization, this represents outstanding progress. IMS volume kept climbing at a solid pace, and on a pro forma basis our HTU brand group's share rose 0.9 points from the same quarter a year earlier, reaching 2.8% in Q3 — a strong result given how seasonality weighed on things. It shows we're winning in plenty of markets, with particularly encouraging movement in Lebanon, where Q3 offtake share in Beirut climbed by +7 points to 18%, and in Egypt, where offtake share in Cairo now sits near 6%. You can find additional TCS data in the appendix. We're also heartened by a favorable regulatory step recently taken in the Philippines, where a new law was passed by the government that draws a clear line between combustible and non-combustible tobacco products. Under it, smoke-free products get their own regulatory track, with distinct health warnings, allowed product technique or testing or guided trials, plus forthcoming rules covering product communication and point-of-sale activity — all of which should help other smokers switch to better alternatives. On top of that, the newest thing out of our smoke-free innovation pipeline is a heat-not-burn device aimed especially at low and middle-income markets. It's a straightforward, easy-to-use, and affordable option that can serve local taste preferences while still preserving the product's reduced risk profile; pilot city launches are planned in Colombia and the Philippines in the fourth quarter, as we keep widening our smoke-free portfolio to meet varied consumer needs. While we keep innovating, weaving sustainability in through eco-design principles, circularity, and work to limit and handle post-consumer waste is essential. Tackling our product's environmental footprint is a central pillar of our sustainability strategy, echoed in our sustainability index and included in our executive compensation scheme. How we go about cutting waste tied to cigarettes, RRP consumable, device, and packaging is detailed in a report, case studies, and campaign released last month and accessible through a dedicated microsite on pmi.com; for instance, we're making good headway toward our 2025 aspiration of having at least 80% of our shipment volumes covered by markets with anti-littering program in place for cigarettes and for over 1 million cumulative smoke-free devices to be refreshed or repaired. Also, in September, over 10,000 stakeholders from upwards of 60 markets took part in cleanup initiative across the globe. Our ESG performance makes me proud, and it keeps earning recognition worldwide. Both our 2021 low carbon transition plan and our business transformation strategy were recently put forward for sustainability prizes, and Jennifer Motles, our Chief Sustainability Officer, was put forward for CSO of the year at the World Sustainability Awards. Turning now to what may be the biggest news of the day, we're thrilled to say that before long we'll hold full control of IQOS, the top smoke-free product in the United States, the biggest smoke-free market anywhere. As we said before, after last year's ITC decision barred IQOS imports into the U.S., we've been talking with Altria to determine the best way ahead. PMI has consistently aimed to secure an outcome that puts IQOS in the strongest possible position to achieve its maximum U.S. potential without delay. I'm pleased to share that we've now secured a result delivering exactly that. First, let me walk through the deal's main provisions in brief. Starting April 30, 2024, PMI gains complete authority regarding IQOS commercialization across the United States, which lets us distribute and sell the product and, importantly, interact with adult tobacco consumers directly. Under this arrangement, we're handing Altria roughly $2.7 billion in total cash; in our view, this deal delivers outstanding shareholder value, similar to the prior arrangement, and could extend through 2029. By sidestepping what might have become a drawn-out, unpredictable legal battle capable of badly impeding IQOS's progress, this resolution brings certainty. It offers a transparent short-term route toward large-scale U.S. commercialization, supported without restriction by PMI's complete strategic and financial dedication to the product's success. Globally, IQOS stands as the top smoke-free offering, having grown impressively and swiftly throughout numerous international markets. Beginning from nothing in 2015, IQOS now constitutes a $9 billion yearly net revenue enterprise, having established the appealing heat-not-burn segment and propelled its expansion. When measured by retail value, America represents the largest accessible nicotine market worldwide.

Emmanuel Babeau

executive
#5

The projected retail value of the expanding smoke-free sector is currently about 60% of the sum of all worldwide markets outside China. We've discussed before how we intend to deliver a top-tier portfolio in the U.S., and we anticipate that IQOS will sit right at the heart of our American smoke-free ambitions, exactly as it does in other places already. The chance for IQOS in the U.S. is especially promising, because American adult smokers clearly want trustworthy smoke-free substitutes for cigarettes. On top of that, existing smoke-free offerings have only partly succeeded in getting adult smokers to abandon cigarettes entirely. Across the U.S., there's plenty of room to develop adult smoker knowledge and comprehension of smoke-free product options — a point that applies especially to IQOS, thanks to our MRTP authorization. We're prepared to put money behind IQOS to launch it broadly throughout the U.S., beginning with full-scale rollouts in major cities and regions, then moving quickly toward nationwide reach. IQOS is still the sole inhalable smoke-free nicotine product that has been granted a modified risk tobacco product authorization by the U.S. Food and Drug Administration. From what we've seen in more than 65 markets around the world, IQOS holds strong appeal for adult smokers who've given it a try, evidenced by the high rate of complete switching. We're firmly dedicated to raising awareness and funding this category to encourage product trial among American smokers. The genuine upside for IQOS in the U.S. is considerable, as shown by the double-digit national shares reached within just a few years in various Asian, European, and other markets — each with differing demographic makeups and adult smoker taste preferences. We think reaching a volume share of 10% of cigarettes and HTUs by 2030 is quite attainable, and there's room to go well beyond that. Crucially, the return on investment for IQOS within the extremely lucrative U.S. tobacco market is highly compelling. We put the total U.S. industry profit pool at more than $20 billion, and the average unit margin on U.S. cigarettes is over three times higher than the PMI average. The payback across the coming years on the consideration paid to Altria appears highly attractive. Since we hold no legacy cigarette business in the U.S., this opportunity is entirely additive. That also mirrors the present excise tax structure, which draws no distinction between heated tobacco products and cigarettes at the federal level, with differentiation only on a limited basis in just a few states — creating a distinct further opportunity as time goes on. We're already far along with our plan for IQOS in the U.S. as we get ready for domestic manufacturing and for key regulatory submissions, among them for IQOS ILUMA, for which we intend to submit a PMTA in H2 2023. As noted earlier, we're aiming at the first half of next year to restart IQOS domestic supply, which Altria will be able to access under our existing arrangement until PMI takes on complete commercial responsibility in April 2024. If our proposed merger with Swedish Match goes through, it would give us specific sales and distribution capabilities in the U.S. But if that deal doesn't work out, we still have a clear route forward for IQOS and the remainder of our smoke-free lineup. The truth is, the heart of the IQOS commercial approach lies in switching adult smokers, not in distribution. Beyond that, the U.S. already has a well-established retail and distribution system with an obvious path to market. So we also have a concrete strategy to move ahead on our own, building and fully controlling and managing U.S. sales and distribution operations across the next 18 months, running up to April 2024, so that we can guarantee a successful IQOS launch and bring in other smoke-free products. That applies if our Swedish Match bid falls through. We genuinely think the agreement we're announcing today is essential to opening up the U.S. smoke-free market. As we've said before, we anticipate that heated tobacco will stay the biggest and quickest-expanding category worldwide when measured in dollars. Although e-vapor, and to a smaller degree nicotine pouches, have cleared the path for smoke-free products in the U.S., we recognize that heated tobacco gets closest to reproducing the experience smokers appreciate, with better conversion rates and extremely limited unintended use. To wrap up today's presentation: our company turned in a robust third quarter and year-to-date results in spite of some difficult headwinds, and we anticipate another outstanding year of double-digit adjusted diluted EPS growth on a pro forma currency-neutral basis. What stood out most was IQOS's ongoing excellent performance, with solid shipment volume and IMS growth, reflecting wide-ranging momentum in the region, Japan, and emerging markets; we're still thrilled by the encouraging results from IQOS ILUMA, our deep pipeline of smoke-free innovation, and our plans for additional launches of both ILUMA and VEEV in the fourth quarter and in 2023; we keep speeding up investment in our commercial program, digital engine, and R&D for long-term growth, along with a number of growth opportunities spanning categories and geographies. The payoff on those investments is still compelling, as shown by the remarkable top and bottom-line growth we've delivered in recent years. Alongside growth in smoke-free products, our combustible business kept performing well, with organic net revenue growth and pro forma shipment volume that was essentially flat. Even with faster pricing in today's inflationary climate, temporary margin strain from inflation and supply chain inefficiency will probably persist over the coming quarters. The key point is that our underlying growth fundamentals are still solid, and we look ahead with confidence. We've locked in near-term access to the sizable U.S. opportunity for IQOS, which also serves as the foundation for rolling out our wider smoke-free portfolio; we're now moving forward with our plan to launch at scale, whether or not Swedish Match is part of it. Lastly, we've raised the dividend annually as a public company through all the highs and lows of economic and currency cycles. We stay firmly dedicated to giving cash back to shareholders as we progress toward our goal of becoming predominantly smoke-free by 2025. Thank you. Prior to opening up the Q&A portion, one thing we should mention is that regarding our bid for Swedish Match, we cannot say anything further than what has already been made public. You can locate every document connected to this offer over at smokefree-offer.com. At this point, Jacek and myself would be glad to take whatever questions you have.

Chris Growe

analyst
#6

Hi. Good morning.

Emmanuel Babeau

executive
#7

Hi, Chris. Good morning.

Chris Growe

analyst
#8

Hello there. First off, if it's alright, I'd like to ask something about the operating margin. If my figures are accurate, I believe it rose by slightly more than 100 basis points so far this year, once you strip out foreign exchange and acquisitions. I'm just trying to get a feel for this: given where the operating margin stands today, and with your forecast calling for a slight decline across the full year, does that factor in a softer operating margin in the fourth quarter? I suppose what I'm after is understanding what's driving that, assuming my calculations are right.

Emmanuel Babeau

executive
#9

Not really, Chris. If you look at where we stand organically before Forex, we're down across the opening nine months, and several effects we've already talked about played into that — obviously the severe supply chain upheaval caused by the conflict in Ukraine and the circumstances in Russia. There's also, naturally, a cost component tied to building out IQOS ILUMA, and yes, that factors in; a great deal of air freight is weighing on the margin as well. A set of short-term factors has been present almost from the start of the year, and those pushed the operating margin lower. My sense is that clearing them away will require some time. On top of that, through the opening nine months we've observed something that clearly isn't going anywhere, namely inflation. Right now the inflation rate we're seeing sits at roughly mid-single digits. It may well intensify, since if you examine inflation levels across many countries, they run higher than those mid-single digit figures. As we've kept saying, we're now beginning to renew a series of contracts that gave us a degree of protection along the way — you know, our purchases of energy and various components — which means this portion of inflation is set to remain; in Q4, in fact, with a more favorable mix and perhaps some one-offs carrying less weight, we anticipate a somewhat improved picture for how margin moves compared with the opening nine months; it's the reverse. We look for Q4, when it comes to margin evolution, to come in better than the opening nine months.

Chris Growe

analyst
#10

All right, thanks. For my second question, it concerns the fact that you raised your volume forecast for the year, which is quite encouraging. Your results so far this year have been really strong. There have been plenty of worries about, you know, consumers trading down, you know, concerns about shoppers being able to, you know, spend on discretionary items, especially in Europe, and especially going forward, as energy costs stay so elevated. Are you noticing any of that, any trading-down behavior, or anything you might share that would give us a clearer sense of how some of your premium brands are performing? Thank you.

Jacek Olczak

executive
#11

Hello, Chris. This is Jacek speaking. Not exactly. When you examine that sort of pressure from consumers trading down, an acceleration in those trends isn't something we're truly observing yet, correct? So clearly, Indonesia and the Philippines are under pressure, yet compared with what we saw previously, not much has really shifted. Someone might make the case that inflation has evolved with somewhat of a lag in certain geographies, but as of today, nothing. You could also tell from Marlboro's shares, correct, that on premium propositions we appear rather strong, all right? Even though we are taking pricing, and there will be, you know, additional pricing down the road.

Chris Growe

analyst
#12

Thank you for that. I appreciate it.

Jacek Olczak

executive
#13

Thank you.

Pamela Kaufman

analyst
#14

Good morning.

Jacek Olczak

executive
#15

Hi, Pam.

Pamela Kaufman

analyst
#16

Hello, and it's obvious that the U.S. represents a major opportunity for both growth and profit when it comes to IQOS, and the fact that you have no existing combustibles operation there works in your favor. If you entered the U.S. via Swedish Match, or instead did so on your own, in what way would your approach to commercialization here differ? Also, how ought investors view the amount of investment needed to bring IQOS to commercial scale in the U.S., along with the effect on your growth algorithm?

Jacek Olczak

executive
#17

Yes. Hello, Pamela. What I'd say is, the thing driving IQOS's success is really that front-end consumer interface, correct? That commercialization piece is among the vital elements behind IQOS's success, and we gauge it by having the industry's top rates for conversion and adoption of IQOS, plus complete switching away from cigarettes. Swedish Match lacks that, correct? What Swedish Match does have is the sales force element, which basically means in-store execution, yet IQOS's success depends on that business-to-consumer piece. Under a bolt-on scenario, clearly that's the investment sitting ahead of us, but, you know, when you weigh it against a great, you know, market size and the profitability pool. Swedish Match brings the sales force element, which is the in-store execution. Clearly it would be, you know, good to have them, but this isn't something that's unique in the sense that, you know, you can't build it or obtain it organically, for instance, okay? Other possibilities could also be on the table. What makes IQOS unique is, once more, the commercial engine, the commercial activations. If you watch us more closely, we've put tremendous effort behind the consumer journey and, you know, automating and digitalizing every touchpoint with consumers, and that's the value we'll bring. Investment will be necessary, but the know-how sits with us.

Pamela Kaufman

analyst
#18

Thanks. I'd like to ask about that 90% threshold tied to the Swedish Match deal, since it looks hard to reach under most scenarios. If fewer shareholders tender, would you think about bringing that threshold down? And what difficulties would come with running the asset while holding a smaller ownership stake?

Jacek Olczak

executive
#19

Well, you know, we've requested some comprehension here, and we aren't receiving that question regarding the Swedish Match deal. The reality is simply this: it's SEK 116 along with that 90% acceptance level, all right? That's where we view Swedish Match's worth — the greatest value available for Swedish Match as of today — and I won't say anything further on the matter. In my view, it's a fair market price, a fair valuation of the company for both shareholder groups, PMI shareholders and Swedish Match shareholders, whether long-term or short-term, and we won't say anything further on this.

Pamela Kaufman

analyst
#20

Understood. Thank you.

Jacek Olczak

executive
#21

Thank you, Pam.

Emmanuel Babeau

executive
#22

Thanks.

Gaurav Jain

analyst
#23

Hello, and good morning.

Jacek Olczak

executive
#24

Morning to you, Gaurav.

Gaurav Jain

analyst
#25

Hello, hello. I've got a few things to ask. To start, regarding the whole strategy for bringing IQOS to market commercially in the U.S., and suppose you're doing this on your own. Hiring will be necessary, and when I look at certain rivals holding a 10% slice of the U.S. market, such as Imperial, they employ a few thousand people. If you need to bring on a few thousand staff and also spend on marketing, then ought we to factor in something like losses amounting to a few hundred million dollars across the initial years, prior to growing IQOS to sufficient volume that it begins producing added EBIT? Similar to what happened when you rolled out IQOS globally. As I recall, roughly from 2015 through 2017, you had something in the range of $700 million or $1 billion in losses that you had flagged back then. Should we expect something comparable as you take the U.S. commercialization forward?

Jacek Olczak

executive
#26

Yes, well, look, broadly speaking, your direction is correct. I mean, clearly, constructing the infrastructure, all of it from nothing, calls for several hundred or thousands of staff. Still, within the framework of the 30,000 people employed by PMI, this isn't our first rodeo putting together an organization from nothing. You're completely right. During the early years, a couple of them will run at a loss, just as, honestly, happened with IQOS in each nation we've entered. If you've been tracking us carefully, you'd know we've reached break-even on markets more quickly than we did during year one or two of our smoke-free journey, compared with what we manage now. There's an enormous amount of learning involved. It's a huge store of learning and capability within the organization. They refer to the internal know-how along with the systems and so on, which we no longer need to build from zero. We understand it quite well — the blueprint — with many elements already having been tested and so forth. The U.S. market is going to benefit from, or make use of, that kind of thing. We'll arrive, sometime next year, with greater clarity regarding how we view the spending and the trajectory. As I believe we stated in the release, the most sensible near-term milestone, given our experience and international success — say 2030 — is 10, 10 points of market share, and if we consider where we stand elsewhere and what we accomplished 6 years afterward, meaning up to today, versus adding roughly 6 years onto the present 2030, 10%, then I think we'll proceed accordingly; we have, and Emmanuel Babeau made it quite plain in his comments that we will give full backing, both financially and in terms of human resources, to secure this success — this long-overdue success for IQOS in the U.S.

Gaurav Jain

analyst
#27

Sure. So now I have a follow-up about the patent dispute at ITC, the BAT litigation, which they won. See, that stops you from bringing in IQOS devices, and that's the reason you're building manufacturing facilities here in the country. Since BAT clearly proved they have some strength in their patents with those wins, couldn't they head to a domestic U.S. court and secure injunctions blocking your sales of IQOS devices within the domestic market as well? I'm trying to figure out how you think about this whole patent litigation, including as it relates to your strategy for making and commercializing IQOS domestically.

Emmanuel Babeau

executive
#28

Well, Gaurav, we need to be clear on that point. The ITC process is one matter, and yes, there is a decision that came from ITC. But apart from that, at the federal circuit, I'd say as of right now, things are going rather well for us. One family of patents that BAT asserted in their ITC case was in fact found invalid before a U.S. court. I don't believe a parallel can be drawn between what took place at the ITC and what's going on at the federal level in the U.S.; our view is that domestic manufacturing provides us a clear path as well as the ability to reenter the U.S. market.

Gaurav Jain

analyst
#29

All right. Could I just pose a single follow-up question regarding your previous comment? When it comes to the IQOS ILUMA device, is it able to avoid every one of those patents that are currently being contested?

Jacek Olczak

executive
#30

The matter that we are involved in — the ITC case that BAT brought — concerns the IQOS 3.0.

Gaurav Jain

analyst
#31

Absolutely, thanks a lot.

Jacek Olczak

executive
#32

Alright. When it comes to ILUMA, the trajectory is entirely distinct.

Gaurav Jain

analyst
#33

Sure. Thank you.

Jacek Olczak

executive
#34

Thank you.

Bonnie Herzog

analyst
#35

Okay, thanks. Hello, all of you. I

Emmanuel Babeau

executive
#36

Hello, Bonnie.

Bonnie Herzog

analyst
#37

Hello. I'd like to start with a question about your guidance. Q3 performed above what you had forecast, and as you're aware, you lifted the currency-neutral revenue outlook for the entire year. What I'm attempting to do is square that with the reduced outlook you've given for IQOS. What this seems to suggest is that you're now anticipating better performance from the combustible segment, and perhaps higher device sales too. Could you take us through that, particularly regarding what you expect for devices during the back half — is there a chance they ramp up? And if retail inventories start piling up, might that have an effect on next year's results?

Emmanuel Babeau

executive
#38

Correct, Bonnie. The device has no bearing whatsoever on the guidance. You're right about that. We've nudged the range for HTU volumes a little. It isn't a huge shift. Previously it stood at 90 to 92, and now it sits at 89 to 91. As you know, a portion of that range remains unchanged. What's clear is that we're seeing some offset from a particularly strong combustible business. I believe I went through that thoroughly during the presentation. That's what provides us with this visibility into volume growth that exceeds what we had previously been expecting, and so we're lifting the guidance to +2%-+3%. On revenue too, we've raised the guidance, with the bottom end of that range now moved up to +6.5%. Adjusted EPS stays where it was, largely because we're seeing costs that could end up somewhat above what we had projected a few weeks back. That leaves us with an unchanged range for adjusted EPS. In short, that's the story of how the guidance has been developing.

Bonnie Herzog

analyst
#39

All right, I appreciate that. Now for my second question. I want to follow up on the deal you signed with Altria, but I'll frame it somewhat differently. What I'm attempting to understand is how you became at ease with paying Altria $2.7 billion, which is a pretty big amount, a single lump sum. This is for regaining your exclusive U.S. rights to IQOS. How sure are you that you can hit a 10% share of the U.S. market by 2030, particularly given that it now seems the ramp will probably be slower if you're going it alone or even alongside Swedish Match? And last, on that same topic, what's your thinking about losing the ability to use the Marlboro brand name in the U.S. at this point?

Jacek Olczak

executive
#40

On the confidence point, Bonnie, look, the confidence behind IQOS keeps increasing annually, quarterly. I mean, you can see what's happening in the international markets, and, you know, some markets we move slower in, some we move faster in. IQOS's potential, the heat-not-burn potential, exists, okay? You know, when we consider the U.S., I don't think — I can't identify any reasons why in the U.S. we couldn't replicate and get near the success we've had internationally. You know, that 10%, if you will, the first double-digit figure, which we reach after six years in every other geography, and bearing in mind that the U.S. is beginning with IQOS 3, and that we'll also be working to bring IQOS ILUMA to the U.S. more quickly. You know, our international success was built on IQOS 2.4, 2.4 Plus. The US is beginning its history, its journey, with IQOS at a far better point from a product standpoint, from our capability standpoint, and from understanding this whole category that we've been in across our international markets; that's where the confidence comes from. The second question regarding Marlboro — IQOS TEREA in Japan is now bigger than the HeatSticks Marlboro by X factor. This was the last market where we were still using the Marlboro trademark on our heat-not-burn consumables. As you know, right at the start, about six years ago, in a few markets, if I remember correctly, Switzerland and Italy, we launched with Marlboro. Very early in the journey we rebranded the thing almost overnight and we removed Marlboro from the brand, from the trade, from the proposition. I actually believe that, you know, we have a Marlboro internationally, and it's a great brand, but on cigarettes. I have no doubt today that we are on a path where we can make IQOS as iconic a brand globally as we previously made Marlboro. To me, this doesn't represent any kind of obstacle or choke point when it comes to what we're doing in the U.S.

Bonnie Herzog

analyst
#41

All right, thanks.

Jacek Olczak

executive
#42

Thanks.

Emmanuel Babeau

executive
#43

Thanks.

Bonnie Herzog

analyst
#44

Thanks. The following question comes from Priya Ohri-Gupta at Barclays. Please go ahead.

Priya Ohri-Gupta

analyst
#45

Hi, thanks a lot for taking my question. To start, I have a quick housekeeping item. How much is the revised Swedish Match offer in U.S. dollars? Do we simply apply the exchange rate as it stands now, or might there be some adjustment tied to hedging that could have been arranged earlier? I also have one more follow-up.

Emmanuel Babeau

executive
#46

Priya, I'm not certain I follow what you're asking. What I mean is, the offer is denominated in Swedish krona, so payment will be made in Swedish krona; what we have reported is that the higher price we're proposing now reflects how the currency has moved between the dollar and the Swedish krona since the May announcement date. Keep in mind that a large share of the cash flow Swedish Match produces is in dollars. That's all. I'm not certain I follow your question.

Priya Ohri-Gupta

analyst
#47

I just wanted to check — you know, at the time you announced the deal, the figure in dollars would have come to $16 billion, and because of the FX movement you're still roughly around that level. Did you add any hedging on top of that?

Emmanuel Babeau

executive
#48

Yes, we can.

Priya Ohri-Gupta

analyst
#49

Has that been confirmed?

Emmanuel Babeau

executive
#50

That calculation is something you can do on your own. The count of Swedish Match shares is available from us, so you can derive it; viewed in dollar terms, my feeling is the number lands somewhat lower. Please bear in mind that Swedish Match does not generate all of its cash flow in dollars, okay? So there's no ambiguity: you cannot just accept that dollar amount as fully accurate — it sits in the 90% to 92% range, not 100%.

Priya Ohri-Gupta

analyst
#51

That's useful. When we consider roughly that 10% share you've talked about reaching by 2030 in the U.S. market, what portion of it involves a contribution from ILUMA? I suppose when you submit the PMTA, or file the PMTA, in the second half of next year, what kind of timeline are you envisioning for that product reaching the market and securing authorization?

Jacek Olczak

executive
#52

Well, what I mean is, we intend to file for PMTA with ILUMA to FDA next year; so, as we've witnessed lately, accounting for when the FDA outcome comes through is somewhat, you know, difficult, but ILUMA will obviously be part of this 10%. I won't tell you right now what portion of the 10% depends on ILUMA, but let's approach it another way. We have a handful of markets, quite successful, yet still only a handful of markets where ILUMA currently has a role in our portfolio. Take, for instance, the European Union, where almost completely, the success of close to six years commercializing IQOS rests on the IQOS 2.4, 2.4 Plus and a 3.1. Those are the products for which we have a fairly clear route into the U.S. ILUMA will be there, but, you know, it's too soon at this point to say what share of the 10% that will be. Obviously, you know, for us, ILUMA delivers advantages that go beyond the blade technology. But regarding blade technology, this is where we stand today, six years into PMI. I think we don't need to resolve that equation today.

Priya Ohri-Gupta

analyst
#53

All right, that's quite useful. One last thing from my side. I believe, as you mentioned, the inflation-related strain is building up due to certain contract renewals you are currently working through on the input side — how should we frame that challenge? Would it be reasonable to view it as moving from the mid-single digits up toward the high single digits? Regarding timing, can we fairly expect the biggest impact to land in the first half of calendar 2023, and then ease somewhat in the back half once you begin to lap some of that? Thanks.

Emmanuel Babeau

executive
#54

Well, regarding the inflation-related strain, it's obviously quite hard to provide anything like a definitive response, since this is a highly fluid scenario with considerable movement. Right now, if we suppose that at some point, the inflation we're confronting will match the inflation observed across many countries — yes, that would likely suggest the mid-single digits might climb into the high single digits. It could be somewhat more complicated than that, since naturally it hinges on which particular component of inflation we're dealing with. In certain areas, that might represent a change for next year. Honestly, it's too soon to tell, and equally too soon to tell when that peak will arrive. Will it come at the close of this year, in terms of costs going up? Will we witness additional inflation throughout 2023? I believe it's too soon to tell. Naturally, I mean, we'll keep watching the situation, but I'd say energy prices are energy prices. Do you follow what I'm saying? There isn't a great deal we can do. We still have to purchase energy. The response to it is naturally to counter through raising prices. I think you've observed in our Q3 a speeding up of our price increases; we're approaching nearly 5%, which demonstrates the ability, depending on whatever the environment turns out to be, to offset the effect of what we'll encounter regarding inflation-related strain by raising prices.

Priya Ohri-Gupta

analyst
#55

Great. Thank you so much.

Emmanuel Babeau

executive
#56

Thank you.

Jacek Olczak

executive
#57

Much appreciated for listening to us; it means a lot that you gave us this hour, particularly right now, which matters greatly to us, since our main strategic priority across the past several months, and arguably beyond that, has centered on securing a far clearer and more predictable route into the United States — something accomplished by closing the agreement with Altria and taking back complete ownership of IQOS. We're delighted you joined us for this hour today. Thanks.

Emmanuel Babeau

executive
#58

Thanks. We'll speak again shortly.

James Bushnell

executive
#59

That wraps up today's call. We appreciate your participation once more. Should any additional questions come up, reach out to the investor relations team. Thanks once more, and enjoy the rest of your day.

Operator

operator
#60

Thank you, ladies and gentlemen; this concludes today's event. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.